High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface.


Journal

Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030

Informations de publication

Date de publication:
19 10 2023
Historique:
received: 04 10 2022
revised: 03 05 2023
accepted: 29 06 2023
medline: 27 10 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: ppublish

Résumé

Identifying virus-host interactions on the cell surface can improve our understanding of viral entry and pathogenesis. SARS-CoV-2, the causative agent of the COVID-19 disease, uses ACE2 as a receptor to enter cells. Yet the full repertoire of cell surface proteins that contribute to viral entry is unknown. We developed a photocatalyst-based viral-host protein microenvironment mapping platform (ViraMap) to probe the molecular neighborhood of the SARS-CoV-2 spike protein on the human cell surface. Application of ViraMap to ACE2-expressing cells captured ACE2, the established co-receptor NRP1, and several novel cell surface proteins. We systematically analyzed the relevance of these candidate proteins to SARS-CoV-2 entry by knockdown and overexpression approaches in pseudovirus and authentic infection models and identified PTGFRN and EFNB1 as bona fide viral entry factors. Our results highlight additional host targets that participate in SARS-CoV-2 infection and showcase ViraMap as a powerful platform for defining viral interactions on the cell surface.

Identifiants

pubmed: 37499664
pii: S2451-9456(23)00207-6
doi: 10.1016/j.chembiol.2023.06.028
pii:
doi:

Substances chimiques

spike protein, SARS-CoV-2 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Spike Glycoprotein, Coronavirus 0
Viral Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1313-1322.e7

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests T.R.-R., K.A.R., T.J.B., J.M.B., C.H.W., D.J.H., K.A.V., E.C.H., O.O.F., and R.C.O. were employed by Merck & Co. during the experimental planning, execution, and preparation of this manuscript. Other authors declare no competing interests.

Auteurs

Suprama Datta (S)

Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA; Center for Network Systems Biology, Boston University, Boston, MA 02118, USA.

Da-Yuan Chen (DY)

Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA.

Alexander H Tavares (AH)

Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA.

Tamara Reyes-Robles (T)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA.

Keun Ah Ryu (KA)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA.

Nazimuddin Khan (N)

Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA.

Tyler J Bechtel (TJ)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA.

Jayde M Bertoch (JM)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA.

Cory H White (CH)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA.

Daria J Hazuda (DJ)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA; Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc, West Point, PA 19486, USA.

Kalpit A Vora (KA)

Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc, West Point, PA 19486, USA.

Erik C Hett (EC)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA.

Olugbeminiyi O Fadeyi (OO)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA. Electronic address: niyi@induprotx.com.

Rob C Oslund (RC)

Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA. Electronic address: rob@induprotx.com.

Andrew Emili (A)

Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA; Center for Network Systems Biology, Boston University, Boston, MA 02118, USA. Electronic address: emili@ohsu.edu.

Mohsan Saeed (M)

Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA. Electronic address: msaeed1@bu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH